File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Article: Asian clinical trial trends by type of sponsor, trial phase, disease area and country

TitleAsian clinical trial trends by type of sponsor, trial phase, disease area and country
Authors
Issue Date2011
PublisherClinical Trials Centre. The University of Hong Kong, Li Ka Shing Faculty of Medicine. The Journal's web site is located at http://www.clinicalresearchclinic.com/default.aspx
Citation
Clinical Trial Magnifier, 2011, v. 4 n. 2, p. 53-68 How to Cite?
AbstractSummary Asian trials are predominantly industry-sponsored phase III trials - 33.8% of all such trials registered are conducted in Asia. About half of the top 30 sponsors have an Asian arm for 25% or more of their phase II trials, and about half of the top 30 sponsors have an Asian arm for 50% or more of their phase III trials. About 70% of all industry-sponsored phase III trials conducted in Japan, India or China have five sites or more per trial compared to about 40% in South Korea, Taiwan and the Philippines. Hong Kong and Singapore have virtually no trial with five or more sites, while some 20% of phase III trials in Thailand and Malaysia have five or more sites. Oncology, endocrinology and cardiovascular trials are most frequently located to Asia. Seoul is the most popular Asian trial city, followed by Beijing, Taipei, Bangalore and Shanghai. It can be foreseen that all four countries in North East Asia will become the most important industry-sponsored emerging clinical trial region.
Persistent Identifierhttp://hdl.handle.net/10722/133673
ISSN

 

DC FieldValueLanguage
dc.contributor.authorKarlberg, JPEen_US
dc.date.accessioned2011-05-24T02:14:23Z-
dc.date.available2011-05-24T02:14:23Z-
dc.date.issued2011en_US
dc.identifier.citationClinical Trial Magnifier, 2011, v. 4 n. 2, p. 53-68en_US
dc.identifier.issn2078-8185-
dc.identifier.urihttp://hdl.handle.net/10722/133673-
dc.description.abstractSummary Asian trials are predominantly industry-sponsored phase III trials - 33.8% of all such trials registered are conducted in Asia. About half of the top 30 sponsors have an Asian arm for 25% or more of their phase II trials, and about half of the top 30 sponsors have an Asian arm for 50% or more of their phase III trials. About 70% of all industry-sponsored phase III trials conducted in Japan, India or China have five sites or more per trial compared to about 40% in South Korea, Taiwan and the Philippines. Hong Kong and Singapore have virtually no trial with five or more sites, while some 20% of phase III trials in Thailand and Malaysia have five or more sites. Oncology, endocrinology and cardiovascular trials are most frequently located to Asia. Seoul is the most popular Asian trial city, followed by Beijing, Taipei, Bangalore and Shanghai. It can be foreseen that all four countries in North East Asia will become the most important industry-sponsored emerging clinical trial region.-
dc.languageengen_US
dc.publisherClinical Trials Centre. The University of Hong Kong, Li Ka Shing Faculty of Medicine. The Journal's web site is located at http://www.clinicalresearchclinic.com/default.aspx-
dc.relation.ispartofClinical Trial Magnifieren_US
dc.rightsClinical Trial Magnifier. Copyright © Clinical Trials Centre. The University of Hong Kong, Li Ka Shing Faculty of Medicine.-
dc.titleAsian clinical trial trends by type of sponsor, trial phase, disease area and countryen_US
dc.typeArticleen_US
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=2078-8185&volume=4&issue=2&spage=53&epage=68&date=2011&atitle=Asian+clinical+trial+trends+by+type+of+sponsor,+trial+phase,+disease+area+and+country-
dc.identifier.emailKarlberg, JPE: jpekarl@hkucc.hku.hken_US
dc.identifier.hkuros185327en_US
dc.identifier.volume4en_US
dc.identifier.issue2en_US
dc.identifier.spage53en_US
dc.identifier.epage68en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats